SRR10899996
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYOGENESIS+0.700
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.400
- KRAS_SIGNALING_DN+0.400
- ADIPOGENESIS+0.300
- ANGIOGENESIS+0.300
- OXIDATIVE_PHOSPHORYLATION+0.300
- UV_RESPONSE_DN+0.300
- APICAL_JUNCTION+0.200
- BILE_ACID_METABOLISM+0.200
- COAGULATION+0.200
Top 10 suppressed
- E2F_TARGETS-0.700
- G2M_CHECKPOINT-0.600
- MYC_TARGETS_V2-0.600
- DNA_REPAIR-0.500
- INTERFERON_ALPHA_RESPONSE-0.500
- MTORC1_SIGNALING-0.500
- MYC_TARGETS_V1-0.500
- UNFOLDED_PROTEIN_RESPONSE-0.500
- PROTEIN_SECRETION-0.400
- CHOLESTEROL_HOMEOSTASIS-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR665298 | GTEX | — | 0.859 |
| 2 | TCGA-BH-A0BM-01A-11R-A056-07 | — | A | 0.837 |
| 3 | SRR35579814 | — | A | 0.835 |
| 4 | SRR614479 | GTEX | — | 0.835 |
| 5 | SRR655435 | GTEX | — | 0.830 |
| 6 | SRR17866845 | — | — | 0.827 |
| 7 | C3L-01890 | — | cohortA2 | 0.826 |
| 8 | TCGA-KQ-A41P-01A-12R-A33J-07 | — | — | 0.822 |
| 9 | SRR1409305 | GTEX | — | 0.819 |
| 10 | SRR1315761 | GTEX | — | 0.818 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 20 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYOGENESIS | 0.700 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.400 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.400 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.300 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.300 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.300 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.300 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.200 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.200 | Inavolisib | — uncovered |
| COAGULATION | 0.200 | Binimetinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.200 | Inavolisib | — uncovered |
| HYPOXIA | 0.200 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.100 | Temsirolimus | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.100 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.100 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.100 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_UP | 0.100 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.100 | Cobimetinib | — uncovered |
| TGF_BETA_SIGNALING | 0.100 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.100 | Inavolisib | — uncovered |